Flavan-3-ols consumption and cancer risk: a meta-analysis of epidemiologic studies
Metrics: PDF 598 views | HTML 2070 views | ?
Lei Lei1,2, Ying Yang1,2, Hongjuan He1,2, Erfei Chen1,2, Le Du1,2, Jing Dong1,2, Jin Yang1,2
1Key Laboratory of Resources Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi’an 710069, China
2Institute of Preventive Genomic Medicine, Xi’an 710069, China
Jin Yang, email: email@example.com
Keywords: meta-analysis, flavan-3-ols, cancer, colorectal cancer, breast cancer
Received: March 29, 2016 Accepted: July 27, 2016 Published: September 14, 2016
Although numerous in vitro studies and animal model data have suggested that flavan-3-ols, the most common subclass of flavonoids in the diet, may exert protective effects against cancer, epidemiologic studies have reported inconclusive results for the association between flavan-3-ols intake and cancer risk. Therefore, we conducted this meta-analysis of epidemiologic studies to investigate the preventive effects of flavan-3-ols on various types of cancers. A total of 43 epidemiologic studies, consisting of 25 case-control and 18 prospective cohort studies, were included. A significant inverse association was shown between flavan-3-ols intake and the risk of overall cancer (relative risk (RR) 0.935, 95%CI: 0.891-0.981). When cancer types were separately analyzed, a statistically significant protective effect of flavan-3-ols consumption was observed in rectal cancer (RR 0.838, 95%CI: 0.733-0.958), oropharyngeal and laryngeal cancer (RR 0.759, 95%CI: 0.581-0.993), breast (RR 0.885, 95%CI: 0.790-0.991) in case-control studies and stomach cancer in women (RR 0.633, 95%CI: 0.468-0.858). Our analysis indicates the potential benefits of flavan-3-ols in cancer prevention.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.